Trial Profile
Pharmacokinetics of Anidulafungin Given Intravenously as Antifungal Prophylaxis to Recipients of an Allogeneic Haematopoietic Stem Cell Transplant Following Myeloablative Chemotherapy or Patients Receiving Intensive Chemotherapy for AML-MDS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Anidulafungin (Primary)
- Indications Mycoses
- Focus Pharmacokinetics
- Acronyms ANIDULAPK
- 07 Sep 2015 New trial record